Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy

BACKGROUND: Atezolizumab was first shown to significantly improve progression-free survival (PFS) after platinum-based chemotherapy in early-stage non-small cell lung cancer (NSCLC) in the IMpower010 Phase 3 trial. However, the cost-effectiveness and potential economic impact of atezolizumab treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ping, Yang, Qing, Li, Yinfeng, Jing, Xiaomei, Chen, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490556/
https://www.ncbi.nlm.nih.gov/pubmed/36158650
http://dx.doi.org/10.3389/fonc.2022.894656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490556/
https://www.ncbi.nlm.nih.gov/pubmed/36158650
http://dx.doi.org/10.3389/fonc.2022.894656

Ejemplares similares